Samsung Biologics has announced that it may expand its manufacturing capacity at its site in Songdo, Incheon. Launched in 2011, Samsung has three plants housing a total of 364,000 L of mostly stainless-steel bioreactor capacity that, according to Samsung’s CEO, will be fully utilized to capacity by 2022. Samsung’s CEO had previously said that “the company will prepare to add a fourth plant and new bio campus” to keep up with the momentum of biomanufacturing demand, and that the “addition of a fourth plant is a plan that is to be studied in the long run.” According to the Nikkei Asian Review, Samsung closed over $1.5 billion worth of orders in the past three months, including a mix of biosimilar and novel antibodies.